Myriad Genetics, Inc. (MYGN) Tops Q1 EPS by 1c, Reaffirms FY12 Guidance
Tweet
Share
E-mailGet Alerts MYGN Hot Sheet
Price: $4.50 -0.88%
EPS Growth %: -220.0%
Financial Fact:
Companion diagnostic services: 12.4M
Today's EPS Names:
OCCI, MAYS, CRMT, More
EPS Growth %: -220.0%
Financial Fact:
Companion diagnostic services: 12.4M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Myriad Genetics, Inc. (NASDAQ: MYGN) reported Q1 EPS of $0.29, $0.01 better than the analyst estimate of $0.28. Revenue for the quarter came in at $110.5 million versus the consensus estimate of $106.49 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ennis (EBF) Reports In-Line Q1 EPS
- CarMax beats estimates as new strategy drives early results
- Accenture tumbles 16% on guidance cut; announces Dragos, runZero, NetRise deals
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
